Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

PEG-MGF: What It Is Studied Alongside

PEG-MGF is a pegylated synthetic analogue of mechano growth factor (MGF), an IGF-1 splice variant. This page summarises the research literature it appears in, including GH-IGF-1 axis peptides, pegylated somatropin, and u

peptides-pro Editorial

PEG-MGF (pegylated mechano growth factor) is a synthetic analogue of mechano growth factor, an IGF-1 splice variant also referred to as IGF-1Ec in human tissue and IGF-1Eb in rodents. It belongs to the IGF-1 peptide family and is supplied as a lyophilised research-grade powder. The pegylation step attaches polyethylene glycol chains to the peptide backbone, a modification intended to extend circulatory residence time relative to the unmodified peptide. The evidence block assembled for this page does not provide a sequence, molecular formula, or molecular weight for PEG-MGF, and none is asserted here. The pathway the work centres on is the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis, the endocrine and local signalling system that links pituitary GH secretion to IGF-1 production in liver and peripheral tissues [1].

PEG-MGF is not itself the subject of the clinical trials listed in the evidence block. The trials that appear alongside it in the literature concern other compounds acting on the same axis or on unrelated pathways, and the sections below separate what is documented from what is not. Where a finding comes from an animal model or an in vitro preparation, that is stated explicitly.

Research Studies

PEG-MGF and the GH-IGF-1 axis peptide class

A review of performance-enhancing peptides marketed as research compounds describes the agents most commonly encountered in clinical practice and online self-administration protocols as those intended to modulate the GH-IGF-1 axis [1]. That class includes GHRH analogues such as sermorelin, tesamorelin, and CJC-1295 with and without Drug Affinity Complex (DAC); growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin, and ipamorelin; the GH fragment AOD9604 (hGH 176-191); and IGF-1 analogues [1]. PEG-MGF sits adjacent to this group by virtue of its IGF-1 lineage, though the review does not name PEG-MGF specifically. The review frames these compounds as unregulated peptides, which is the regulatory context in which PEG-MGF is also supplied.

PEG-MGF and pegylated somatropin in Turner syndrome

The closest structural parallel in the evidence block is a clinical trial of PEG-somatropin injection in children with Turner syndrome [8]. That study was designed to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection, to preliminarily evaluate its safety and efficacy, and to provide evidence for dosing in a Phase 3 trial [8]. The population was paediatric patients with Turner syndrome. The pegylation strategy — attaching PEG chains to a peptide to alter its pharmacokinetic profile — is the same general approach used in PEG-MGF, but the two molecules are not the same and the trial does not involve PEG-MGF. No efficacy or safety data from that trial are reported in the evidence block, and none is inferred here.

PEG-MGF and the IGF-1 analogue subgroup

Within the GH-IGF-1 axis review, IGF-1 analogues are listed as one of the agent categories encountered in self-administration protocols [1]. PEG-MGF is an IGF-1 splice variant analogue rather than a direct IGF-1 analogue, so it is not identical to the compounds in that subgroup. The review does not provide separate outcome data for IGF-1 analogues, and no claim about PEG-MGF's effects can be drawn from its inclusion in the class description. What the review does establish is that this family of compounds is used outside regulated clinical channels, which is relevant to how the research literature should be read.

PEG-MGF and mechanotransduction research

Mechano growth factor is named for its association with mechanical loading of muscle. The evidence block does not contain a study that measures PEG-MGF in a mechanotransduction model, and no such study is described here. Any statement that PEG-MGF is studied in resistance-exercise or muscle-loading paradigms would require a source that the evidence block does not supply. The absence of that source is noted rather than filled.

PEG-MGF and Alzheimer's disease trial contexts

Several trials in the evidence block concern Alzheimer's disease and do not involve PEG-MGF or the GH-IGF-1 axis. A trial of trontinemab assessed efficacy and safety in participants with early symptomatic Alzheimer's disease, from mild cognitive impairment to mild dementia due to Alzheimer's disease [2]. A separate pre-screening study assessed potential eligibility for Roche interventional Alzheimer's disease studies [3]. Two trials of semaglutide in early Alzheimer's disease, EVOKE and EVOKE Plus, each randomised participants to semaglutide or placebo, ran for up to 173 weeks, and required a study partner [4][5]. These trials appear in the same search space as PEG-MGF only because of indexing overlap; they provide no information about PEG-MGF.

PEG-MGF and cardiovascular trial contexts

Two cardiovascular studies appear in the evidence block without any connection to PEG-MGF. One was conducted to improve knowledge about the epidemiology of lipoprotein(a) in patients with established cardiovascular disease [6]. The other, THALES, investigated whether ticagrelor and ASA were more effective than placebo and ASA in preventing new stroke events in acute stroke or transient ischaemic attack [7]. Neither study involves PEG-MGF, and neither is presented here as supporting evidence for it.

PEG-MGF and the limits of the current evidence block

The evidence block does not contain a primary study of PEG-MGF in any model. It contains a class-level review of GH-IGF-1 axis peptides [1], a pegylated GH trial in a paediatric Turner syndrome population [8], and five trials in Alzheimer's disease or cardiovascular disease that are unrelated to PEG-MGF [2][3][4][5][6][7]. No animal-only or in vitro PEG-MGF data are present in the block, so no such data are reported. Where a reader encounters claims about PEG-MGF in cell culture or rodent models, those claims rest on sources outside this page.

PEG-MGF and the compounds it is most often discussed with

The table below compares the compounds named in the evidence block by their relationship to PEG-MGF. It is a map of the literature, not a comparison of effects.

Compound or class Relationship to PEG-MGF Evidence in block
GHRH analogues (sermorelin, tesamorelin, CJC-1295 with/without DAC) Same axis, different receptor level Named in review [1]
Growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin) Same axis, different receptor level Named in review [1]
AOD9604 (hGH 176-191) GH fragment, same axis Named in review [1]
IGF-1 analogues Same family, different splice or analogue Named in review [1]
PEG-somatropin (PEG-rhGH) Same pegylation strategy, different peptide Turner syndrome trial [8]
Trontinemab No relationship Alzheimer's trial [2]
Semaglutide No relationship EVOKE and EVOKE Plus [4][5]
Ticagrelor and ASA No relationship THALES [7]

PEG-MGF is supplied as a research-grade material under the formal name PEG-MGF. It is not a therapeutic product and is not represented as one.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.

Sources

WhatsApp